Marjolein de Bruin-Weller1, Andrew E Pink2, Annalisa Patrizi3, Ana M Gimenez-Arnau4, Tove Agner5, Pierre-Paul Roquet-Gravy6, Silvia M Ferrucci7, Petr Arenberger8, Ake Svensson9, Marie L A Schuttelaar10, Audrey Nosbaum11, Shyamalie Jayawardena12, Elena Rizova13, Marius Ardeleanu14, Laurent Eckert15, Zafer E Ozturk13. 1. National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands. 2. St. John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 3. Department of Dermatology, IRCCS Policlinico di S. Orsola, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy. 4. Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain. 5. Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. 6. Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium. 7. Department of Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 8. Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. 9. Skåne University Hospital, Malmo, Sweden. 10. Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. 11. Allergy and Clinical Immunology Department, University of Lyon, Lyon Sud University Hospital, Pierre Benite, France. 12. Sanofi, Bridgewater, NJ, USA. 13. Sanofi Genzyme, Cambridge, MA, USA. 14. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. 15. Sanofi, Chilly-Mazarin, France.
Abstract
BACKGROUND: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. METHODS: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. RESULTS: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and ≥1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator's Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. CONCLUSIONS: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.
BACKGROUND: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. METHODS: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. RESULTS: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and ≥1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator's Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. CONCLUSIONS: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.
Entities:
Keywords:
Atopic dermatitis; patient-reported outcomes; quality of life; systemic therapy
Authors: Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor Journal: Adv Ther Date: 2022-09-05 Impact factor: 4.070
Authors: Diamant Thaçi; Andrea Bauer; Ralph von Kiedrowski; Florian Schenck; Konstantin Ertner; Sophie Möller; Anja Fait; Mike Bastian; Matthias Augustin Journal: Dermatol Ther (Heidelb) Date: 2022-08-19